biotech
(314)
Switzerland Innovation Park Basel Area sells scientists a head start
A biotech company can lose months before its first experiment. In the Basel Area, shared labs and room to grow turn the landlord into part of the research strategy.
IKP Knowledge Park and the expensive art of getting science to market
A laboratory can prove an idea. Building a business requires rather more plumbing. In Hyderabad and Bengaluru, IKP Knowledge Park has spent decades assembling the missing pieces.
Storm3 starts the search before the job exists
The HealthTech recruiter bets that the person you need next is already busy elsewhere. Its business is knowing them before you need an introduction.
The Cell Had an Alibi. The Camera Kept Watching.
A cell can look ordinary at noon and turn resistant by night. Cellanome built a machine to keep watching - then read the RNA of the very cells in the film.
Rezo Is Betting the Best Drug Targets Hide Between Proteins
Drug discovery usually isolates a culprit. Rezo maps the whole criminal network - then asks which handshake can be broken with a small molecule.
The Medical Meeting That Refuses to End
Impact Communication Partners has spent more than four decades translating complicated science for healthcare professionals. Its sharpest idea is also its simplest: the best answer may arrive after the meeting is over.
The Most Important Person in the Picture Is Not the Patient
Living in the Light has spent more than a decade making rare-disease stories less clinical and more human. Its method begins with a small but radical edit: move the diagnosis out of the center of the frame.
The Best Therapy in the World Still Needs Someone to Say Yes
MEYA Health works in the awkward distance between scientific approval and real-world access - where evidence must become a story that payers, health systems and field teams can actually use.
Torch Communications sells the hard part: getting through
A biotech announcement, a billionaire’s investment firm, a hospital software story. Torch Communications works where complicated ideas meet people with limited patience.
Twist Medical and the patient in the byline
A medical communications agency is helping patients enter the scientific conversation as contributors. Its publication credits show what that work looks like - and why listening is only the beginning.
SmiLe gives biotech founders a lab - and lets them keep their equity
At Sweden’s SmiLe Venture Hub, shared laboratories come with business coaches, industry introductions and a patient timetable. The proposition is practical: spend less effort assembling the infrastructure, and more proving the business.
Lyonbiopôle works on biotech’s other problem: who opens the next door?
A promising discovery still needs partners, money and a route to patients. Lyonbiopôle has spent two decades organizing those introductions - and its new strategy puts the business end of science under the microscope.
H7 BioCapital starts with the buyer
The healthcare investor puts licensing and acquisition demand near the start of the startup journey. Its accelerator, angel syndicate and conference circuit turn that thesis into introductions, coaching and deal-by-deal investment.
Basel’s business card comes with a lab
Basel Area Business & Innovation puts relocation advice, biotech venture building and innovation campuses under one roof. Its bet: the right introduction can be as useful as the first cheque.
District 3 Takes No Equity. Bring Your Time.
At Concordia’s startup incubator, founders keep their shares and face some awkward questions. The real investment is learning what customers will actually pay for.
Qualio Turned the FDA’s Paperwork Problem Into a $64 Million Software Bet
A pharmacist saw life-science teams trying to prove product quality with paper, spreadsheets and disconnected software. Fourteen years and roughly $64 million in funding later, Qualio is betting that audit readiness can become a continuous operating system - with humans still holding the pen.
The Startup Rebuilding the Organ That Quietly Ages You
Most of biotech chases the diseases you can see. Thymmune went after the organ almost no one thinks about - the thymus - and built a way to grow it from stem cells.
The Rice-Sized Sensor Trying to End the IVF Blood-Test Marathon
A fertility patient can give blood every other day for weeks and still miss the hormone surges that decide whether a cycle works. Impli wants to put a continuous read of that biology under the skin - or on it.
The Boston Biotech Betting That Cells Don't Have to Show Up to Heal You
Aegle Therapeutics skips the stem cell transplant and ships only the message the cell was trying to send - a cell-free vesicle therapy now in human trials for one of the cruelest skin diseases in medicine.
Neurogazer Turns a 40-Minute Brain Scan Into a Report Card for Who You Might Become
A Johns Hopkins neuroscientist and his CEO brother built a company that reads 169 things out of a single MRI - cognition, temperament, aptitude, risk. From Baltimore, they are betting families will pay to see it.
The Duke Spinout Teaching Billion-Dollar Drugs to Fit Inside a Needle
Deborah Bitterfield raised about $8 million over seven years to prove that a protein could be dried into microbeads and shot through a needle. Then Novartis signed a deal worth up to nearly $1 billion.
The Pregnancy Test That Could Catch a Killer Before the Doctor Does
Preeclampsia kills tens of thousands of mothers a year, mostly because no one catches it in time. A team that started as classmates in Durham and Kampala wants to move that first warning from the hospital lab to the bathroom shelf.
Shiru Built an "Amazon for Proteins" - and It Wants to Kill Palm Oil
A protein biochemist got tired of ingredient hunts that take 15 years. So she built a search engine for nature's proteins - and its first product is a fat that behaves like butter without the palm oil.
The Minneapolis Shop That Turns Lab IP Into Real Companies
Most venture firms write checks and wait. Invenshure hires the scientists, licenses the patents, and builds the company itself - one hard problem at a time.
The Startup Teaching Ventilator Patients to Breathe on Their Own Again
Every long stint on a ventilator quietly weakens the one muscle you need to breathe. XN Health's Phlex device stimulates the phrenic nerve through the breathing tube to keep the diaphragm working - and get patients off the machine sooner.
The Psychedelic Fund That Grew Into a Bet on the Whole Brain
PsyMed Ventures started with a podcast and a narrow question about psychedelic medicine. Six years later, its portfolio makes a broader wager: that the next important health companies will treat the brain as biology, data and lived experience at once.
The Firm That Buys Fortune 100 Leftovers and Turns Them Into Companies
Big companies spend billions on R&D and then quietly bury most of it. Catalyze Partners digs it back up, staffs it, funds it, and sells it - and lets investors own the whole shelf.
The Only Two Bets BlueYard Will Make: Utopia or Oblivion
BlueYard hands early-stage founders a check between $500K and $5M to chase problems most investors call radioactive - fusion reactors, hypersonic defense, decentralized money, engineered cells. Since 2016 it has backed Solana, Groq, IonQ and Filecoin from a partnership split between Berlin and the US.
The Fund Betting That 60% of the Economy Will Soon Be Grown, Not Made
Jennifer Kan spent years at a Nobel laureate's bench teaching enzymes new tricks. Now her fund backs the founders trying to grow the physical economy - chocolate, copper, chemicals, even data - one engineered cell at a time.
The Firm That Bets on the Toolmakers, Not the Cure
For nearly four decades, Ampersand Capital Partners has skipped the lottery of drug discovery and quietly backed the companies that make the drug discovery possible. In May 2026 it closed a $1.5 billion fund in a single day.